Education
About Us
Working with TipRanks
Follow Us
IDNA - ETF AI Analysis
Top Page
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA)
Rating:57Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown strong gains over the past month, three months, and year to date, indicating positive recent momentum.
Leading Biotech and Pharma Holdings
Several of the largest positions, including well-known biotech and pharmaceutical companies, have delivered strong year-to-date performance that supports the fund’s returns.
Global Healthcare Exposure
While most holdings are in the U.S., the fund also invests in companies from Europe and Asia, adding some international diversification within the healthcare theme.
Negative Factors
High Sector Concentration
With almost all assets in the healthcare sector, the ETF is heavily exposed to swings in one industry rather than the broader market.
Moderate Fee Level
The expense ratio is higher than many broad market ETFs, which means a larger share of returns goes toward fees each year.
Mixed Performance Among Top Holdings
A few of the largest positions have shown weak or negative year-to-date performance, which could drag on the fund if those stocks continue to lag.
IDNA vs. SPDR S&P 500 ETF (SPY)
AUM149.63M
RegionGlobal
Expense Ratio0.47%
Beta0.91
IssueriShares
Inception DateJun 11, 2019
Dividend Yield1.03%
Asset ClassEquity
Index TrackedNYSE FactSet Global Genomics and Immuno Biopharma Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume23,051
30 Day Avg. Volume35,580
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
37.79Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering49
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IDNA Summary
IDNA is an ETF that follows the NYSE FactSet Global Genomics and Immuno Biopharma Index, focusing on companies using genetics and immune-based science to develop new drugs and medical treatments. It mainly holds healthcare and biotech firms involved in gene editing, genome sequencing, and advanced cancer and immune therapies. Well-known holdings include Moderna and Merck. Someone might invest in IDNA if they believe in the long-term growth of cutting-edge medical technology and want targeted exposure to this theme. A key risk is that it is heavily concentrated in healthcare and biotech, so its price can be very volatile and move sharply up or down.
How much will it cost me?The iShares Genomics Immunology and Healthcare ETF (IDNA) has an expense ratio of 0.47%, which means you’ll pay $4.70 per year for every $1,000 invested. This is slightly higher than average because it’s a sector-focused fund that requires active management to track innovative companies in genomics and healthcare. The higher cost reflects the specialized nature of the fund.
What would affect this ETF?The IDNA ETF, focused on genomics and healthcare innovation, could benefit from advancements in gene editing, personalized medicine, and increased global healthcare spending, which may drive growth in its top holdings like Revolution Medicines and Regeneron. However, it faces risks from regulatory hurdles, high research costs, and potential market volatility in the healthcare sector, which could impact the performance of companies within the fund. Global economic conditions and changes in government healthcare policies could also influence the ETF's future performance.
IDNA Top 10 Holdings
IDNA is a pure play on global biotech and drug innovation, with health care names dominating the lineup. Moderna and Revolution Medicines are the main engines right now, both rising on optimism around their pipelines and keeping the fund’s growth story alive. Established giants like Roche and Merck are steadier hands, adding stability rather than fireworks. On the softer side, BioNTech looks a bit tired after earlier excitement, while Regeneron’s mixed recent moves show that even strong franchises can wobble in this volatile corner of the market.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Moderna | 6.34% | $9.47M | $18.21B | 47.35% | 59 Neutral | |
| Bayer | 4.88% | $7.29M | €45.00B | 99.42% | 54 Neutral | |
| Ipsen | 4.64% | $6.94M | €13.01B | 44.70% | 70 Outperform | |
| Takeda Pharmaceutical Co | 4.63% | $6.93M | ¥9.21T | 32.08% | 66 Neutral | |
| Revolution Medicines | 4.55% | $6.81M | $19.29B | 143.11% | 52 Neutral | |
| GlaxoSmithKline | 4.42% | $6.61M | £91.50B | 53.84% | 77 Outperform | |
| Roche Holding AG | 4.35% | $6.50M | CHF294.84B | 47.36% | 73 Outperform | |
| Merck & Company | 4.31% | $6.45M | $301.96B | 38.98% | 80 Outperform | |
| BioNTech SE | 4.05% | $6.05M | $25.96B | -6.33% | 53 Neutral | |
| Regeneron | 3.85% | $5.75M | $83.73B | 12.41% | 78 Outperform |
IDNA Technical Analysis
Positive
―
Price Trends
27.87
Positive
26.52
Positive
23.88
Positive
Market Momentum
0.44
Negative
64.56
Neutral
96.35
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IDNA, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 29.17, equal to the 50-day MA of 27.87, and equal to the 200-day MA of 23.88, indicating a bullish trend. The MACD of 0.44 indicates Negative momentum. The RSI at 64.56 is Neutral, neither overbought nor oversold. The STOCH value of 96.35 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDNA.
IDNA Peer Comparison
Comparison Results
Performance Comparison
IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund
30.00
7.19
31.52%
IVES
Dan IVES Wedbush AI Revolution ETF
―
―
―
BUG
Global X Cybersecurity Etf
―
―
―
NUKZ
Range Nuclear Renaissance Index ETF
―
―
―
GII
SPDR S&P Global Infrastructure ETF
―
―
―
IHAK
iShares Cybersecurity & Tech ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents